Work Here?
Industries
Healthcare
Consumer Goods
Company Size
51-200
Company Stage
Series A
Total Funding
$22.2M
Headquarters
San Francisco, California
Founded
2016
Multiply Labs specializes in creating personalized vitamins and supplements tailored to individual health needs. Their process uses advanced technology to analyze factors like age, lifestyle, and health goals, allowing them to formulate effective supplement regimens for each customer. This company primarily targets health-conscious consumers, including fitness enthusiasts and those with specific dietary requirements. Unlike many competitors, Multiply Labs operates on a direct-to-consumer model, selling products through their website and offering subscriptions for recurring revenue. Their goal is to provide customized nutritional solutions that enhance individual health and wellness.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$22.2M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Work from home option
Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).
Progentos Therapeutics, a biotech company developing a novel regenerative medicine for multiple sclerosis (MS), has launched after securing US$65 million in Series A funding.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform. This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more patients. “Cell therapy manufacturing infrastructure and its associated costs have severely limited the accessibility of cell therapies. Multiply Labs’ automation strategy has the potential to modularize and simplify cell therapy production to ensure greater patient impact. We are very excited to contribute to the Multiply Labs team’s vision by integrating our next generation cell engineering approach with their robotics,” said Armon Sharei, Founder and CEO of Portal. Portal’s mechanoporation technology has demonstrated the capability to deliver many different types of cargo to a broad range of cell types while preserving normal cell function
Longevity biotech Retro Biosciences has entered into an $85 million agreement with Multiply Labs to enhance the production of its cell therapies aimed at age-related diseases.
SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Retro Biosciences (Retro), a biotechnology company developing therapies that meaningfully address age-related diseases, today announced a first-of-its-kind commercial and supply agreement valued at up to $85 million to automate Retro’s groundbreaking approach. Retro, supported by a recent investment by Sam Altman (CEO of OpenAI), is driven by a mission to extend healthy human lifespan by a decade, targeting the cellular drivers of aging. With this partnership, Multiply Labs marks the first commercial sale of its robotic system, in support of Retro’s efforts. This partnership underscores the versatility of Multiply Labs’ robotic systems, showcasing their wide range of cell therapy applications, which include but are not limited to CAR-T therapy manufacturing. The robotic systems can be used broadly to reduce costs, accelerate product timelines, and improve scalability for different types of cell therapies, as well as to automate manufacturing processes for both autologous and allogeneic therapies. By enabling Retro to manufacture at a cost-efficient scale, Multiply Labs empowers them to expedite the transition from process development to clinical trials and commercialization, ultimately expediting the development and delivery of life-changing therapies to patients worldwide
Find jobs on Simplify and start your career today
Industries
Healthcare
Consumer Goods
Company Size
51-200
Company Stage
Series A
Total Funding
$22.2M
Headquarters
San Francisco, California
Founded
2016
Find jobs on Simplify and start your career today